HK1118095A1 - Annexin for cancer risk assessment - Google Patents

Annexin for cancer risk assessment

Info

Publication number
HK1118095A1
HK1118095A1 HK08109111.7A HK08109111A HK1118095A1 HK 1118095 A1 HK1118095 A1 HK 1118095A1 HK 08109111 A HK08109111 A HK 08109111A HK 1118095 A1 HK1118095 A1 HK 1118095A1
Authority
HK
Hong Kong
Prior art keywords
annexin
risk assessment
cancer risk
tissue
urogenital
Prior art date
Application number
HK08109111.7A
Other languages
English (en)
Inventor
Michael Cahill
Andre Schrattenholz
Original Assignee
Proteosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05011042A external-priority patent/EP1724585A1/en
Application filed by Proteosys Ag filed Critical Proteosys Ag
Publication of HK1118095A1 publication Critical patent/HK1118095A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08109111.7A 2005-05-21 2008-08-15 Annexin for cancer risk assessment HK1118095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05011042A EP1724585A1 (en) 2005-05-21 2005-05-21 Annexin for cancer risk assessment
EP05026092A EP1724586A3 (en) 2005-05-21 2005-11-30 Annexin for cancer risk assessment
PCT/EP2006/004818 WO2006125580A1 (en) 2005-05-21 2006-05-22 Annexin for cancer risk assessment

Publications (1)

Publication Number Publication Date
HK1118095A1 true HK1118095A1 (en) 2009-01-30

Family

ID=36940167

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109111.7A HK1118095A1 (en) 2005-05-21 2008-08-15 Annexin for cancer risk assessment

Country Status (10)

Country Link
US (1) US8409812B2 (ko)
EP (2) EP1724586A3 (ko)
JP (1) JP2008545634A (ko)
KR (1) KR20080016809A (ko)
AT (1) ATE511653T1 (ko)
AU (1) AU2006251380B2 (ko)
CA (1) CA2608306A1 (ko)
HK (1) HK1118095A1 (ko)
PL (1) PL1889067T3 (ko)
WO (1) WO2006125580A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2467335C2 (ru) * 2006-06-09 2012-11-20 Протеосис Аг Моноклональные антитела против аннексина а3 для обнаружения карциномы простаты
JP2008202978A (ja) * 2007-02-16 2008-09-04 Hirosaki Univ 前立腺癌の診断方法
JP2010523990A (ja) * 2007-04-12 2010-07-15 プロテオシス アクチエンゲゼルシャフト アネキシンａ３による前立腺癌の自己免疫制御
FR2919063B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
WO2009019368A2 (fr) 2007-07-19 2009-02-12 bioMérieux Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
JP5754767B2 (ja) 2009-02-04 2015-07-29 国立大学法人東京工業大学 Ｐｓａの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法
JP5630757B2 (ja) 2009-10-30 2014-11-26 国立大学法人東京工業大学 Ｐｓａの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法
FR2968767B1 (fr) 2010-12-08 2012-12-21 Biomerieux Sa Procede et coffret pour le diagnostic in vitro du cancer de la prostate
WO2013076222A1 (en) 2011-11-23 2013-05-30 Proteosys Ag Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer
AU2012346594B2 (en) * 2011-11-30 2017-12-21 Agency For Science, Technology And Research GM1 ganglioside to Annexin V microparticle polypeptide ratio for biological monitoring
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
FR2991777B1 (fr) 2012-06-07 2015-08-21 Biomerieux Sa Procede de detection et/ou de dosage de l'annexine a3 d'un mammifere dans le sang ou au moins un de ses derives
JPWO2016031816A1 (ja) 2014-08-26 2017-06-15 学校法人慶應義塾 抗がん剤の感受性の判定マーカー
CA3068688A1 (en) * 2017-06-30 2019-01-03 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511829B1 (en) * 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
WO2002012280A2 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20040033502A1 (en) * 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
WO2002080754A2 (en) 2001-04-03 2002-10-17 Theseus Imaging Corporation Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2002082076A2 (en) * 2001-04-03 2002-10-17 Merck Patent Gmbh Renal cell carcinoma tumor markers
US20030108963A1 (en) * 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003058201A2 (en) 2001-12-31 2003-07-17 Quark Biotech, Inc. Methods for identifying marker genes for cancer
EP1953244A1 (en) * 2002-01-09 2008-08-06 Nakamura, Yusuke Cancer profiles
DE10302422A1 (de) * 2003-01-21 2004-07-29 Responsif Gmbh Medikament und Verwendung zur Tumortherapie
EP2295976A1 (en) * 2003-03-08 2011-03-16 Auvation Ltd Markers for colorectal cancer
PL1720611T3 (pl) 2004-02-16 2010-09-30 Proteosys Ag Marker diagnostyczny dla raka
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
RU2467335C2 (ru) * 2006-06-09 2012-11-20 Протеосис Аг Моноклональные антитела против аннексина а3 для обнаружения карциномы простаты

Also Published As

Publication number Publication date
AU2006251380A1 (en) 2006-11-30
EP1889067B1 (en) 2011-06-01
EP1889067A1 (en) 2008-02-20
JP2008545634A (ja) 2008-12-18
PL1889067T3 (pl) 2011-10-31
EP1724586A2 (en) 2006-11-22
AU2006251380B2 (en) 2011-05-19
EP1724586A3 (en) 2007-07-04
US20100267051A1 (en) 2010-10-21
CA2608306A1 (en) 2006-11-30
WO2006125580A1 (en) 2006-11-30
US8409812B2 (en) 2013-04-02
ATE511653T1 (de) 2011-06-15
KR20080016809A (ko) 2008-02-22

Similar Documents

Publication Publication Date Title
HK1118095A1 (en) Annexin for cancer risk assessment
WO2006081473A8 (en) Methods for diagnosis and prognosis of epithelial cancers
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2010056351A3 (en) Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
WO2009055820A3 (en) Salivary protein biomarkers for human oral cancer
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2009036427A3 (en) Prostate cancer biomarkers
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2004050707A3 (de) Tumorspezifische erkennungsmoleküle
WO2011072177A3 (en) Biomarker assay for diagnosis and classification of cardiovascular disease
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
WO2006083852A3 (en) Luca2 and antibodies that bind thereto
WO2006138219A3 (en) Methods of diagnosis / prognosis of inflammatory conditions
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2006121912A3 (en) Diagnostic methods for the detection of risk of neurodevelopmental disorders
WO2005076939A3 (en) Assay and method for diagnosing and treating alzheimer’s disease
WO2009014565A3 (en) Methods for diagnosing and treating astrocytomas
WO2002057786A3 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
WO2009151693A3 (en) Imaging mass spectrometry for improved prostate cancer diagnostics
WO2006088940A3 (en) Neoplasia screening compositions and methods of use
EP1993672A4 (en) NA / K-ATPase LIGAND

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150522